The cancer-reducing effect of ALK TKI on CMS1 was demonstrated in a 3D spheroid model and in a physiologic mouse model, supporting the potential for a clinical trial using combination therapy containing ALK TKI to treat the CMS1 subtype of colon cancer [64,65,66]. The gene discussed is ALK; the disease is malignant colon neoplasm.